The lived experience of patients with breast cancer on adjuvant endocrine therapy: side effects and coping strategies during the first year of medication initiation.
The lived experience of patients with breast cancer on adjuvant endocrine therapy: side effects and coping strategies during the first year of medication initiation.
复制标题
乳腺癌患者接受辅助内分泌治疗的生活经验：药物治疗第一年的副作用和应对策略。
DOI：
10.1007/s00520-023-08170-y
复制
发表时间：
2023
期刊：
影响因子：
--
通讯作者：
Wen,Kuang-Yi
中科院分区：
文献类型：
--
作者：
Gomaa,Sameh;Lopez,AnaMaria;Slamon,Rachel;Smith,Rita;Lapitan,Emmanuel;Nightingale,Ginah;Miller,SuzanneM;Wen,Kuang-Yi
目的辅助内分泌治疗 (AET) 对于激素受体阳性乳腺癌患者至关重要，可显着提高生存率。然而，由于副作用，坚持 AET 仍然具有挑战性。这项研究深入探讨了乳腺癌幸存者关于 AET 引起的副作用的生活经历，并检查了他莫昔芬和芳香酶抑制剂 (AI) 之间症状特征的差异。方法我们采访了 35 名使用 AET 的乳腺癌幸存者，使用扎根理论进行定性迭代分析。开发了密码本来帮助数据编码和解释。 NVIVO 软件促进了全面的转录分析。结果幸存者报告了一系列副作用，如潮热、性问题、关节疼痛、僵硬、情绪波动和生育问题。症状特征因 AET 类型而异。他莫昔芬使用者会经历更频繁的性副作用和情绪波动，而人工智能则与关节疼痛、僵硬和骨骼健康担忧有关。服用 AET 超过 6 个月的患者表达了对副作用的高度担忧。结论 与 AET 类型一致的定制患者教育使幸存者能够使用自我调节策略来管理副作用。认识到不同的症状特征可以做出明智的决定，提高依从性和生活质量。意义这项研究强调了量身定制的生存支持，为患者提供了管理副作用的工具，提高了依从性和长期结果。研究结果为综合生存计划的整合提供了信息，强调管理副作用和促进更好的依从性和改善生活质量的个性化策略。
PurposeAdjuvant endocrine therapy (AET) is pivotal for hormone receptor-positive breast cancer patients, significantly enhancing survival rates. Yet, adherence to AET remains challenging due to side effects. This study delves into the lived experience of breast cancer survivors concerning AET-induced side effects and examines differences in symptom profiles between Tamoxifen and aromatase inhibitors (AIs).MethodsWe interviewed 35 breast cancer survivors on AET, conducting qualitative iterative analysis using grounded theory. A codebook was developed to aid data coding and interpretation. NVIVO software facilitated comprehensive transcript analysis.ResultsSurvivors reported a spectrum of side effects like hot flashes, sexual issues, joint pain, stiffness, mood swings, and fertility concerns. Symptom profiles differed based on AET type. Tamoxifen users experienced more frequent sexual side effects and mood swings, while AIs were linked to joint pain, stiffness, and bone health worries. Those on AET for over 6 months expressed heightened concerns about side effects.ConclusionTailored patient education, aligned with AET type, empowers survivors to manage side effects using self-regulatory strategies. Acknowledging distinct symptom profiles enables informed decisions, improving adherence and quality of life.ImplicationsThis study underscores tailored survivorship support, equipping patients with tools to manage side effects, enhancing adherence, and long-term outcomes. The findings inform the integration of comprehensive survivorship programs, emphasizing individualized strategies for managing side effects and promoting better adherence and improved quality of life.